We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Correvio Pharma Corporation | NASDAQ:CORV | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.4199 | 0.4311 | 0.35 | 0 | 01:00:00 |
NEW YORK, April 20, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, continues to investigate whether the following proposed mergers are fair to shareholders. Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders:
Wright Medical Group N.V. (NASDAQ: WMGI)
The investigation concerns whether Wright Medical and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders in connection with the proposed sale of Wright Medical to Stryker Corporation for $30.75 per share. If you are a Wright Medical shareholder and would like to learn more about your legal rights and options, please visit: https://halpersadeh.com/actions/wright-medical-group-nv-stock-merger-stryker-corporation/.
Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH)
The investigation concerns whether Tetraphase and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders in connection with the proposed sale of Tetraphase to AcelRx Pharmaceuticals, Inc. for 0.6303 shares of AcelRx for each share of Tetraphase. If you are a Tetraphase shareholder and would like to learn more about your legal rights and options, please visit: https://halpersadeh.com/actions/tetraphase-pharmaceuticals-inc-ttph-stock-merger-acelrx/.
Correvio Pharma Corp. (NASDAQ: CORV)
The investigation concerns whether Correvio and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders in connection with the proposed sale of Correvio to ADVANZ PHARMA Corp. Limited for $0.42 per share. If you are a Correvio shareholder and would like to learn more about your legal rights and options, please visit: https://halpersadeh.com/actions/correvio-pharma-corp-corv-stock-merger-advanz/.
Pacific Premier Bancorp, Inc. (NASDAQ: PPBI)
The investigation concerns whether Pacific Premier Bancorp, Inc. and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders in connection with the proposed sale of Opus Bank to Pacific Premier Bancorp, Inc. If you are a Pacific Premier shareholder and would like to learn more about your legal rights and options, please visit: https://halpersadeh.com/actions/pacific-premier-bancorp-inc-ppbi-stock-merger-opus-bank/.
Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email sadeh@halpersadeh.com or zhalper@halpersadeh.com.
Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Halper Sadeh LLP
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
sadeh@halpersadeh.com
zhalper@halpersadeh.com
https://www.halpersadeh.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/shareholder-investigation-halper-sadeh-llp-investigates-the-following-mergers-are-shareholders-getting-a-fair-deal-301043964.html
SOURCE Halper Sadeh LLP
Copyright 2020 PR Newswire
1 Year Correvio Pharma Chart |
1 Month Correvio Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions